Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects.
Hong ZhangQingmei LiXiaoxue ZhuCuiyun LiXiaojiao LiChengjiao LiuYue HuGuiling ChenHaijing WeiJing WangZhenwei ShenYanhua DingPublished in: Cancer chemotherapy and pharmacology (2018)
The bevacizumab biosimilars exhibit similar PK characteristics to that of the reference product bevacizumab-EU. The inter-CV is moderate and less than 25% in all cases. The safety profile was similar among bevacizumab biosimilars and bevacizumab-EU with significant adverse events.